Skip to main content

Table 2 HD IL-2 dose limiting toxicities reported for cycle 1 of treatment

From: A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

 

Ipi only (n = 52)

No prior ICB (n = 276)

Total (n = 328)

Cardiac

13

18.57

84

24.56

97

23.33

Renal

12

17.14

51

14.91

63

15.29

Neurologic

5

7.14

52

15.2

57

13.83

Gastrointestinal

10

14.29

36

10.53

46

11.17

Hematologic

7

10

34

9.94

41

9.76

Metabolic

5

7.14

30

8.77

41

9.76

Pulmonary

10

14.29

19

5.6

29

7.38

Capillary Leak Syndrome

2

2.86

17

4.97

19

4.52

Hepatic

2

2.86

13

3.8

15

3.57

Skin

4

5.71

6

1.75

10

2.38

Total

70

100

342

100

412

100.0

  1. The first column represents the number of times a toxicity was reported among the entire cohort of patients. The second is the percentage of each individual toxicity as compared to the total number of events. The total events add up to more than the number of patients as some patients reported more than one dose limiting toxicity, up to a maximum of three